尼古丁贴片联合电子烟(含或不含尼古丁)用于戒烟:一项实用性随机试验
该实用性三臂平行组随机试验在新西兰纳入1124名有意戒烟的成年吸烟者(电子烟初用者),按1:4:4随机分为尼古丁贴片组(n=125)、贴片联合含尼古丁电子烟组(n=500)、贴片联合不含尼古丁电子烟组(n=499),均接受14周21 mg 24小时贴片(戒烟日前2周开始)及6周电话行为支持。主要终点为约定戒烟日后6个月呼出气CO验证的持续戒烟。含尼古丁电子烟组6个月戒烟率7%,高于不含尼古丁电子烟组4%(RD 2.99,95%CI 0.17-5.81)和单用贴片组2%(RD 4.60,95%CI 1.11-8.09)。严重不良事件组间无显著差异,且均与治疗无关。
要点
- 在电子烟初用且有意戒烟的成人吸烟者中,贴片联合含尼古丁电子烟6个月CO验证持续戒烟率为7%(35/500)。
- 贴片联合含尼古丁电子烟戒烟率高于贴片联合不含尼古丁电子烟(7% vs 4%,RD 2.99,95%CI 0.17-5.81)。
- 贴片联合含尼古丁电子烟戒烟率高于单用贴片(7% vs 2%,RD 4.60,95%CI 1.11-8.09)。
- 严重不良事件组间无显著差异且均与治疗无关;含尼古丁电子烟组报告2例危及生命的严重不良事件(同一参与者两次独立心脏病发作)。
- 含尼古丁电子烟组6个月失访或退出161/500(32%),不含尼古丁电子烟组162/499(33%),单用贴片组62/125(50%)。
适用人群与场景
- 新西兰成年吸烟者,电子烟初用者,有意戒烟,从一般人群通过全国媒体广告招募。
处置流程与药物剂量
- 所有参与者接受14周(约定戒烟日前2周开始)21 mg、24小时尼古丁贴片,建议每日一片。
- 电子烟按需或期望时使用;含尼古丁电子烟浓度为18 mg/L。
- 提供6周电话传递的行为支持。
研究设计与关键结果
- 实用性、三臂、平行组随机试验,纳入1124名参与者,随机分为贴片组(n=125)、贴片联合含尼古丁电子烟组(n=500)、贴片联合不含尼古丁电子烟组(n=499)。
- 主要终点为约定戒烟日后6个月呼出气CO验证的持续戒烟:含尼古丁电子烟组35/500(7%),不含尼古丁电子烟组20/499(4%),RD 2.99(95%CI 0.17-5.81);单用贴片组3/125(2%),RD 4.60(95%CI 1.11-8.09)。
- 严重不良事件:含尼古丁电子烟组16人发生18起,不含尼古丁电子烟组22人发生27起,单用贴片组3人发生4起;组间无显著差异,且均与治疗无关。
- 含尼古丁电子烟组报告2例危及生命的严重不良事件(同一参与者两次独立心脏病发作);不含尼古丁电子烟组发生1例死亡(意外药物过量)和1例危及生命的严重不良事件(心脏病发作)。
证据类型、等级与局限
- 实用性随机试验;原文未报告证据等级或推荐强度。
- 局限:原文指出需关注差异性失访和退出,并建议未来电子烟试验应聚焦于单独使用或与常规戒烟支持联合,鉴于以常规护理组作为对照时存在差异性失访和退出问题。
对床旁实践的改变
- 作者认为,将减害尼古丁产品(如尼古丁贴片联合含尼古丁电子烟)联合使用,可在贴片联合不含尼古丁电子烟或单用贴片的基础上,适度改善戒烟率,短期未提示任何严重危害。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Combination nicotine replacement therapy shows additive cessation benefits. We aimed to find out the effectiveness of combining nicotine patches with an e-cigarette (with and without nicotine) on six-month smoking abstinence.
METHODS: We did a pragmatic, three-arm, parallel-group trial in New Zealand in adult smokers who were e-cigarette naive and motivated to quit smoking. Participants were recruited from the general population using national media advertising. Participants were randomly assigned (1:4:4), with the use of stratified block randomisation, to receive 14 weeks (2 weeks before the agreed quit date) of 21 mg, 24h nicotine patches, patches plus an 18 mg/L nicotine e-cigarette, or patches plus a nicotine-free e-cigarette. We advised participants to use one patch daily, with e-cigarette use as and when necessary or desired. Participants and researchers were masked to e-liquid nicotine content. We offered 6 weeks of telephone-delivered behavioural support. The primary outcome was exhaled carbon monoxide (CO)-verified continuous smoking abstinence 6 months after the agreed quit date. Primary analysis was by intention to treat, with sensitivity analysis by per protocol, treatment adherence, varying CO cutoffs, and complete case analysis. This paper presents the main analyses and is registered with ClinicalTrials.gov, NCT02521662.
FINDINGS: Between March 17, 2016 and Nov 30, 2017, 1124 people were assigned to nicotine patches (patches only group, n=125), patches plus a nicotine e-cigarette (patches plus nicotine e-cigarette group, n=500), or patches plus a nicotine-free e-cigarette (patches plus nicotine-free e-cigarette group, n=499). 62 (50%) of 125 participants in the patches only group withdrew or were lost to follow-up by 6 months compared with 161 (32%) of 500 in the patches plus nicotine e-cigarette group and 162 (33%) of 499 in the patches plus nicotine-free e-cigarette group. 35 (7%) participants in the patches plus nicotine e-cigarette group had CO-verified continuous abstinence at 6 months compared with 20 (4%) in the patches plus nicotine-free e-cigarette group (risk difference [RD] 2·99 [95% CI 0·17-5·81]), and three (2%) people in the patches only group (RD 4·60 [1·11-8·09]). 18 serious adverse events occurred in 16 people in the patches plus nicotine e-cigarette group compared with 27 events in 22 people in the patches plus nicotine-free e-cigarette group and four events in three people in the patches only group. In the patches plus nicotine e-cigarette group, two life-threatening serious adverse events were reported (two separate heart attacks in the one participant). In the patches plus nicotine-free e-cigarette group, one death occurred (accidental drug overdose) and one life-threatening serious adverse event (heart attack). No significant between-group differences were noted for serious adverse events, and none were treatment-related.
INTERPRETATION: Combining reduced-harm nicotine products, such as nicotine patches with a nicotine e-cigarette, can lead to a modest improvement in smoking cessation over and above that obtained from using patches plus a nicotine-free e-cigarette (or patches alone), with no indication of any serious harm in the short-term. Future e-cigarette trials should focus on their use alone or in combination with usual smoking cessation support, given issues with differential loss to follow-up and withdrawal if a usual care group is used as a comparator.
FUNDING: Health Research Council of New Zealand.
参考来源
- Walker N, Parag V, Verbiest M, et al. Nicotine patches used in combination with e-cigarettes (with and without nicotine) for smoking cessation: a pragmatic, randomised trial. Lancet Respir Med. 2019. PMID: 31515173. doi:10.1016/S2213-2600(19)30269-3
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。